Investment Thesis
Xylem demonstrates solid financial health with strong liquidity (1.62x current ratio), excellent interest coverage (34.9x), and conservative leverage (0.17x debt/equity), providing a stable foundation. The company generates substantial free cash flow of $910M with a healthy 10.1% FCF margin, supporting operations and potential shareholder returns, though revenue growth stagnation and modest ROE of 8.3% suggest the business is mature and capital efficiency could improve.
XYL Strengths
- Exceptional interest coverage ratio of 34.9x indicates minimal financial distress risk
- Strong free cash flow generation of $910M demonstrates ability to fund operations and capital allocation
- Conservative leverage with debt-to-equity of 0.17x and substantial equity base of $11.5B
- Healthy gross margin of 38.5% and operating margin of 13.5% show pricing power and cost control
- Solid liquidity position with current ratio of 1.62x and $1.5B cash balance
XYL Risks
- Revenue growth stalled at 0.0% YoY, indicating market saturation or competitive pressures in pumping equipment sector
- ROE of 8.3% and ROA of 5.4% are modest, suggesting inefficient capital deployment relative to equity base
- Net income growth of only 0.7% YoY despite EPS growth of 7.4% indicates share buybacks masking underlying earnings weakness
- Capital expenditure of $331M represents only 3.7% of revenue, potentially indicating underinvestment in growth initiatives
- Significant insider activity with 21 Form 4 filings in 90 days warrants monitoring for potential management confidence signals
Key Metrics to Watch
- Revenue growth trajectory - critical indicator of whether market demand stabilizes or deteriorates
- Return on equity (ROE) improvement - needs to exceed 10% to demonstrate efficient capital allocation
- Free cash flow margin sustainability - maintain above 10% to ensure continued dividend and reinvestment capacity
- Operating margin trends - watch for compression that would indicate competitive or cost pressures
- Debt reduction progress - opportunity to further improve leverage given strong FCF generation
XYL Financial Metrics
XYL Profitability Ratios
XYL Balance Sheet & Liquidity
XYL 5-Year Financial Trend
5-Year Trend Summary: Xylem Inc.'s revenue has grown significantly by 23% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.79 reflects profitable operations.
XYL Growth Metrics (YoY)
XYL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1B | $153.0M | $0.89 |
| Q2 2025 | $2.2B | $153.0M | $0.80 |
| Q1 2025 | $2.0B | $153.0M | $0.63 |
| Q3 2024 | $2.1B | $152.0M | $0.63 |
| Q2 2024 | $1.7B | $92.0M | $0.45 |
| Q1 2024 | $1.4B | $99.0M | $0.54 |
| Q3 2023 | $1.4B | $12.0M | $0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
XYL Capital Allocation
XYL SEC Filings
Access official SEC EDGAR filings for Xylem Inc. (CIK: 0001524472)